Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.
Also called NCT01880216
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 312 participants
- Sponsor
- Berlin-Chemie AG Menarini Group
- Registry
-
NCT01880216
-
- Other papers using this trial's data
- Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Georgia, Russia
- Registry status
- Completed
Technical summary
Registry record NCT01880216. Randomized; single masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
- Condition
- Deep Vein Thrombosis
- Intervention (Drug)
- Bemiparin sodium
- Intervention (Drug)
- Enoxaparin sodium
- Lead sponsor
- Berlin-Chemie AG Menarini Group
Record details
- Record id
cardio:ct-nct01880216- Content hash
1ac5223620f11cef62028d9b1631ae93de3df7146fb703bbbb873a4129dc2f66